On Biostatistics and Clinical Trials
CQ's web blog on the issues in biostatistics and clinical trials.
Showing posts with label
Recommended Phase 2 Dose
.
Show all posts
Showing posts with label
Recommended Phase 2 Dose
.
Show all posts
Sunday, January 18, 2026
Maximal Tolerated Dose (MTD) to Recommended Phase 2 Dose (RP2D) - a shift in early oncology trial designs
›
As the field of oncology moves from systemic cytotoxic chemotherapies to targeted agents and immunotherapies, the paradigm for dose selecti...
›
Home
View web version